LBL.H — Lattice Biologics Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Annual income statement for Lattice Biologics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2016 September 30th | 2017 September 30th | 2018 September 30th | 2019 September 30th | 2020 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.85 | 2.74 | 1.16 | 2.19 | 2.46 |
| Cost of Revenue | |||||
| Gross Profit | 0.616 | 0.571 | 0.541 | 0.943 | 1.02 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.92 | 3.58 | 2.01 | 2.75 | 2.84 |
| Operating Profit | -3.07 | -0.845 | -0.86 | -0.565 | -0.375 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.35 | -1.52 | -1.23 | -1.01 | -1.48 |
| Net Income After Taxes | -6.35 | -1.52 | -1.23 | -1.01 | -1.48 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.35 | -1.52 | -1.23 | -1.01 | -1.48 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.35 | -1.52 | -1.23 | -1.01 | -1.48 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.122 | -0.041 | -0.018 | -0.011 | -0.014 |